Detalhe da pesquisa
1.
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Leuk Lymphoma
; 59(7): 1659-1665, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29179634